IL-17 and IL-17 receptor inhibitors boast an impressive safety history and are widely available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to prevent acute respiratory distress syndrome (ARDS) in coronavirus disease 2019 (COVID-19) and discuss why we think that a clinical trial of a drug in this class could be a logical addition to the effort to find effective therapies. Levels of the cytokine IL-17 positively correlate with disease severity in COVID-19. Here, the authors argue that existing anti-IL-17 therapies should be considered for the treatment of severe COVID-19.

中文翻译：

---

COVID-19：抑制IL-17的案例？

IL-17和IL-17受体抑制剂具有令人印象深刻的安全历史，并且被广泛使用。在这里，我们认为靶向IL-17作为在2019年冠状病毒疾病（COVID-19）中预防急性呼吸窘迫综合征（ARDS）的策略在免疫学上是可行的，并讨论了我们为什么认为该类药物的临床试验可以寻找有效疗法的努力的合乎逻辑的补充。在COVID-19中，细胞因子IL-17的水平与疾病的严重程度呈正相关。在这里，作者认为应考虑使用现有的抗IL-17疗法治疗重症COVID-19。